Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.77 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | FBP1 | P09467 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7809280 | 0.99 | EGFR (0.75) | EGFRERBB2MAPK1FBP1HTT | |
| SCHEMBL8871114 | 0.87 | EGFR (0.59) | EGFRERBB2MAPK1FBP1HTT | |
| SCHEMBL2988532 | 0.87 | EGFR (0.59) | EGFRERBB2MAPK1FBP1HTT | |
| SCHEMBL8315497 | 0.86 | EGFR (0.79) | EGFRERBB2MAPK1FBP1HTT | |
| SCHEMBL8088219 | 0.85 | EGFR (0.79) | EGFRERBB2MAPK1FBP1HIF1A | |
| SCHEMBL27369686 | 0.84 | EGFR (0.72) | EGFRERBB2FBP1ABCG2 | |
| SCHEMBL7802761 | 0.84 | EGFR (0.72) | EGFRERBB2FBP1ABCG2 | |
| Hydrochloric Acid SCHEMBL1507670 | 0.83 | EGFR (0.71) | EGFRERBB2FBP1ABCG2 | |
| SCHEMBL27923394 | 0.82 | EGFR (0.70) | EGFRMAPK1FBP1HTTABCG2 | |
| SCHEMBL2995375 | 0.82 | EGFR (0.92) | EGFRFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0635498-B1 | Quinazoline derivatives and their use as anti-cancer agents | SYNGENTA LTD (GB) | 2001-04-18 | — | — | EP | disclosed |
| EP-0823901-B1 | QUINAZOLINE DERIVATIVE | ZENECA LTD (GB) | 2000-10-18 | — | — | EP | disclosed |
| EP-0635507-B1 | Tricyclic derivatives and their use as anti-cancer agents | ZENECA LTD (GB) | 1999-09-15 | — | — | EP | disclosed |
| US-5952333-A | INHIBITOR OF TYROSINE KINASE RECEPTOR FOR TREATING PROLIFERATIVE DISEASE SUCH AS CANCER | ZENECA LIMITED (GB) | 1999-09-14 | — | — | US | disclosed |
| EP-0823901-A1 | QUINAZOLINE DERIVATIVE | ZENECA LIMITED (GB) | 1998-02-18 | — | — | EP | disclosed |
| US-5616582-A | Use as anticancer agents; e.g. gefitinib | ZENECA LIMITED (GB) | 1997-04-01 | — | — | US | disclosed |
| WO-1996033981-A1 | QUINAZOLINE DERIVATIVE | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |
| US-5569658-A | Tricyclic derivatives | ZENECA LIMITED (GB) | 1996-10-29 | — | — | US | disclosed |
| US-5475001-A | Quinazoline derivatives | ZENECA LIMITED (GB) | 1995-12-12 | — | — | US | disclosed |
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| WO-1995003283-A1 | QUINAZOLINE DERIVATIVES AND THEIR USE AS ANTI-CANCER AGENTS | ZENECA LIMITED (GB) | 1995-02-02 | — | — | WO | disclosed |
| EP-0635507-A1 | Tricyclic derivatives and their use as anti-cancer agents | ZENECA LIMITED (GB) | 1995-01-25 | — | — | EP | disclosed |
| EP-0635498-A1 | Quinazoline derivatives and their use as anti-cancer agents | ZENECA LIMITED (GB) | 1995-01-25 | — | — | EP | disclosed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | disclosed |